Zhongxin Finance, February 11. On the 11th, Chen Jinfu, deputy director of the National Medical Security Administration, said at a regular briefing on the reform of the State Council on deepening the reform of centralized procurement of drugs and high-value medical consumables. We do not particularly anchor the international lowest price, because China is on the road to common prosperity, we Chinese people can also take good medicine, and medical insurance funds can also afford this kind of medicine at a reasonable price.

　　According to Chen Jinfu, centralized procurement is a major institutional innovation and a reform of system integration. This kind of reform is not a matter of a single goal, but a dynamic balance of multiple goals. In other words, there must be system integration, strict rules, scientific and fairness The "Bingdundun" of the company must also have a "Xue Rongrong" that has a dynamic balance of multiple goals, benefits from multiple parties, and promotes future development.

　　Chen Jinfu said that at the institutional level, it is necessary to insist on purchasing with quantity, to ensure quality, to promote innovation-driven, to stabilize supply, and to ensure clinical use.

In the next step, we must strengthen the platform construction, make it serve the market, serve medical institutions, serve enterprises, and conduct professional platform operations.

These can not be deviated from now or in the future, especially the procurement with quantity is the core of the system.

If they "follow the price but not the volume", the company cannot compete with the price, it is impossible to implement effective cost accounting, and it has to go to the hospital, which increases the operating cost and leaves room for profit.

　　At the rule level, it is to serve the system level, Chen Jinfu said, setting bidding rules for specific varieties and competition patterns.

At the same time, it is necessary to moderate competition according to the market supply situation.

We do not pursue the lowest price, and we firmly oppose running bidding, so that the balance of multiple dynamic goals cannot be achieved.

The design of this competition rule actually has a mechanism for reasonable price adjustment, how to make the market discover value and make fair bidding more reasonable for enterprises.

(Finish)